See today's BioWorld Asia
To read the full story, subscribe or sign in.

Azura Ophthalmics raises $20M series C for registration study in Meibomian gland dysfunction

Oct. 27, 2020
By Tamra Sami
PERTH, Australia – Azura Ophthalmics Ltd. raised a $20 million series C round with existing investors, including Brandon Capital’s Medical Research Commercialization Fund (MRCF), Orbimed, TPG Biotech and Ganot Capital.
BioWorld Asia Financings Ocular Series C Australia